Literature DB >> 32063398

Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy.

Delia Cortés-Guiral1, Faheez Mohamed2, Olivier Glehen3, Guillaume Passot3.   

Abstract

Treatment of peritoneal malignancy with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) is often undertaken in patients who have nutritional, physical and psychological challenges as a result of advanced disease. Prehabilitation is a multimodal approach that helps optimize postoperative recovery and reduce morbidity and may be of benefit in this group of patients. It begins once the decision to operate is made and continues until recovery to baseline health. Here we present recommendations on Prehabilitation for patients undergoing cytoreductive surgery and HIPEC following discussion at the 10th Peritoneal Malignancy Workshop in Paris September 2018.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Cytoreductive surgery; HIPEC; Peritoneal malignancy; Prehabilitation

Mesh:

Year:  2020        PMID: 32063398     DOI: 10.1016/j.ejso.2020.01.032

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  7 in total

1.  Guide to Enhanced Recovery for Cancer Patients Undergoing Surgery: ERAS for Patients Undergoing Cytoreductive Surgery with or Without HIPEC.

Authors:  Ankit Dhiman; Emily Fenton; Jeffrey Whitridge; Jennifer Belanski; Whitney Petersen; Sarah Macaraeg; Govind Rangrass; Ardaman Shergill; Dejan Micic; Oliver S Eng; Kiran Turaga
Journal:  Ann Surg Oncol       Date:  2021-05-05       Impact factor: 5.344

Review 2.  Primary and metastatic peritoneal surface malignancies.

Authors:  Delia Cortés-Guiral; Martin Hübner; Mohammad Alyami; Aditi Bhatt; Wim Ceelen; Olivier Glehen; Florian Lordick; Robert Ramsay; Olivia Sgarbura; Kurt Van Der Speeten; Kiran K Turaga; Manish Chand
Journal:  Nat Rev Dis Primers       Date:  2021-12-16       Impact factor: 52.329

3.  Randomized Controlled Trial Investigating Perioperative Immunonutrition for Patients Undergoing Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  Grace Hwei Ching Tan; Claramae Shulyn Chia; Jolene Si Min Wong; Whee Sze Ong; Hong-Yuan Zhu; Chin-Ann Johnny Ong; Melissa Ching Ching Teo
Journal:  Ann Surg Oncol       Date:  2022-09-30       Impact factor: 4.339

Review 4.  Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups.

Authors:  O Glehen; V Kepenekian; O Bouché; L Gladieff; C Honore
Journal:  J Visc Surg       Date:  2020-04-23       Impact factor: 2.043

5.  Physical, psychological and nutritional outcomes in a cohort of Irish patients with metastatic peritoneal malignancy scheduled for cytoreductive surgery (CRS) and heated intrapertioneal chemotherapy (HIPEC): An exploratory pilot study.

Authors:  Lisa Loughney; Noel McCaffrey; Claire M Timon; Joshua Grundy; Andrew McCarren; Ronan Cahill; Niall Moyna; Jurgen Mulsow
Journal:  PLoS One       Date:  2020-12-09       Impact factor: 3.240

6.  Enhanced recovery after surgery (ERAS) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a cross-sectional survey.

Authors:  Geetu Bhandoria; Sohan Lal Solanki; Mrugank Bhavsar; Kalpana Balakrishnan; Cherukuri Bapuji; Nitin Bhorkar; Prashant Bhandarkar; Sameer Bhosale; Jigeeshu V Divatia; Anik Ghosh; Vikas Mahajan; Abraham Peedicayil; Praveen Nath; Snita Sinukumar; Robin Thambudorai; Ramakrishnan Ayloor Seshadri; Aditi Bhatt
Journal:  Pleura Peritoneum       Date:  2021-06-21

7.  Effect of Preoperative Immunonutrition on Postoperative Major Morbidity after Cytoreductive Surgery and HIPEC in Patients with Peritoneal Metastasis.

Authors:  Alba Fernández-Candela; Alicia Calero; Luís Sánchez-Guillén; Javier Escrig-Sos; José A Barreras; Francisco López-Rodríguez-Arias; Laura Armañanzas; Ana Murcia; Antonio Arroyo; Francisco Javier Lacueva
Journal:  Nutrients       Date:  2021-06-23       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.